MYL Mylan NV

   By Stephen Nakrosis 
 

Pharmaceutical company Mylan N.V. (MYL) on Friday announced the commercial launch of Hulio, a biosimilar to AbbVie's Humira, across major markets in Europe.

The company said the product is approved for all adalimumab indications and will be available to patients as soon as possible.

The European Commission approved Hulio in September 2018, following the adoption of a positive opinion by the Committee for Medicinal Products for Human Use. The EC approval of Hulio applies to all 28 European Union member countries and European Economic Area member states of Norway, Iceland and Liechtenstein, the company said.

Hulio is indicated for the same indications of Humira, including rheumatoid arthritis, psoriatic arthritis, psoriasis and Crohn's disease in adults and plaque psoriasis and Crohn's disease in children.

Humira is the world's best-selling biologic medication.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

October 19, 2018 13:26 ET (17:26 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.